脆弱类杆菌
结直肠癌
荟萃分析
医学
产肠毒素大肠杆菌
微生物学
拟杆菌
内科学
生物
癌症
抗生素
细菌
肠毒素
遗传学
大肠杆菌
基因
作者
Shijun Xia,Lijuan Ma,Hui Li,Yue Li,Linchong Yu
标识
DOI:10.3389/fcimb.2025.1525609
摘要
Introduction The gut microbiome, specifically enterotoxigenic Bacteroides fragilis (ETBF), has been reported to play a role in colorectal cancer development. We aimed to conduct a systematic review and meta-analysis of published studies to compare the prevalence of ETBF in patients with colorectal cancer and healthy controls as well as in various stages of colorectal cancer. Methods PubMed, EMBASE, and The Cochrane Library were systematically searched for studies published until May 2024. We utilized studies either comparing the prevalence of ETBF in patients with colorectal cancer and healthy control or examining its prevalence across different stages of colorectal cancer. The prevalence of ETBF colonization in biological samples from individuals with colorectal cancer compared to that in healthy controls or adjacent normal tissue as well as the association between the prevalence of ETBF and various stages of colorectal cancer were plotted using a random-effect or fixed-effect model. Results Fourteen relevant articles were identified. Meta-analyses revealed that patients with colorectal cancer had a higher likelihood of having ETBF than healthy controls (odds ratio [OR]: 2.54, 95% confidence interval [CI]: 1.63–3.98, I 2 = 55%). Additionally, ETBF detection was lower in stage I/II than in stage III/IV colorectal cancer (OR: 0.61, 95% CI: 0.41–0.91, I 2 = 41%). Discussion The prevalence of ETBF was consistently higher in the tissue and fecal samples of patients with colorectal cancer than in those of controls. A difference in ETBF prevalence between stage I/II and stage III/IV colorectal cancer was noted, but further analysis revealed that the conclusion is unreliable. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD 42024548325.
科研通智能强力驱动
Strongly Powered by AbleSci AI